Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IVVD
Strong SellSinkerInvivyd, Inc. · Healthcare · United States · $284M · Avg Vol: $3M/d
COMPANY DESCRIPTION
Invivyd, Inc. is a biopharmaceutical company focused on developing novel antibody therapeutics for infectious diseases, particularly those caused by rapidly evolving viruses. The company utilizes a proprietary platform to engineer antibodies with enhanced breadth and potency. Invivyd aims to address unmet medical needs in viral prevention and treatment, targeting a significant global health challenge.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | 0 | 0 | 25.4M | 53.4M | 110.5% | 58.4M | 60.1M | 87.0M | 27.6% |
| EPS | -5.32 | -0.83 | -0.68 | -0.58 | -0.30 | — | -0.31 | -0.57 | -0.55 | — |
| Shares | — | 294.6M | 294.6M | 294.6M | 282.0M | -4.3% | 294.8M | — | — | — |
| Debt | — | 3.7M | 2.2M | 1.3M | 2.5M | -12.5% | 8.4M | — | — | — |
| Equity | — | 356.0M | 177.5M | 67.5M | 241.5M | -12.1% | — | — | — | — |
| Op CF | — | -220.0M | -173.2M | -170.5M | -58.1M | — | -108.4M | — | — | — |
| Inv CF | — | -230.7M | 280.7M | -0.1M | -0.2M | — | — | — | — | — |
| Fin CF | — | 0.5M | 1.0M | 39.3M | 215.6M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IVVD are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IVVD | Invivyd, Inc.(you) | $284M | 12 | Strong Sell |
| RNAC | Cartesian Therapeutics, Inc. | $290M | 12 | Strong Sell |
| TTRX | Turn Therapeutics Inc. | $299M | 13 | Strong Sell |
| PYXS | Pyxis Oncology, Inc. | $269M | 15 | Strong Sell |
| SION | Sionna Therapeutics, Inc. | $265M | 14 | Strong Sell |
| TRDA | Entrada Therapeutics, Inc. | $273M | 10 | Strong Sell |
| AVXL | Anavex Life Sciences Corp. | $277M | 9 | Strong Sell |
| CAMP | CAMP4 THERAPEUTICS CORPORATION | $260M | 10 | Strong Sell |
| ELDN | Eledon Pharmaceuticals, Inc. | $260M | 15 | Strong Sell |
| SRZN | Surrozen, Inc. | $264M | 9 | Strong Sell |
Peer medians: ROE -30.2% · P/E 27.0x · Gross margin 58.1%